Thomas Goddemeier
Merck Healthcare KGaA, Darmstadt (Germany) · 18 works · 1,812 citations · h-index 11
Top works
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
- Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
- Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
- Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
- Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
- Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial
- A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer
- A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.
- Phase I dose‐escalation trial of Sym004, an anti‐ EGFR antibody mixture, in Japanese patients with advanced solid tumors
- A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
- 9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy
- A phase Ia/Ib trial of the DNA-dependent protein kinase inhibitor (DNA-PKi) M3814 in combination with radiotherapy in patients with advanced solid tumors.
- Simple-to-use, reference criteria for revealing drug-induced QT interval prolongation in conscious dogs
- Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
- Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
- Phase IB Trial of Imo-2055 in Combination with 5-Fu, Cisplatin and Cetuximab in 1st-Line PTS with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
- Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.